- Home
- VVV vs IONS Comparison
VVV vs IONS Comparison
Compare VVV & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVV
- IONS
- Stock Information
- Founded
- VVV 1866
- IONS 1989
- Country
- VVV United States
- IONS United States
- Employees
- VVV N/A
- IONS N/A
- Industry
- VVV Major Chemicals
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- VVV Industrials
- IONS Health Care
- Exchange
- VVV Nasdaq
- IONS Nasdaq
- Market Cap
- VVV 4.7B
- IONS 4.6B
- IPO Year
- VVV 2016
- IONS 1991
- Fundamental
- Price
- VVV $33.48
- IONS $28.40
- Analyst Decision
- VVV Buy
- IONS Buy
- Analyst Count
- VVV 11
- IONS 18
- Target Price
- VVV $44.00
- IONS $57.00
- AVG Volume (30 Days)
- VVV 1.8M
- IONS 2.0M
- Earning Date
- VVV 05-07-2025
- IONS 04-30-2025
- Dividend Yield
- VVV N/A
- IONS N/A
- EPS Growth
- VVV N/A
- IONS N/A
- EPS
- VVV 2.08
- IONS N/A
- Revenue
- VVV $1,659,900,000.00
- IONS $705,138,000.00
- Revenue This Year
- VVV $9.14
- IONS N/A
- Revenue Next Year
- VVV $14.43
- IONS $25.80
- P/E Ratio
- VVV $15.93
- IONS N/A
- Revenue Growth
- VVV 11.85
- IONS N/A
- 52 Week Low
- VVV $31.02
- IONS $23.95
- 52 Week High
- VVV $48.27
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- VVV 44.21
- IONS 44.54
- Support Level
- VVV $32.88
- IONS $27.57
- Resistance Level
- VVV $34.73
- IONS $29.04
- Average True Range (ATR)
- VVV 1.45
- IONS 1.79
- MACD
- VVV 0.02
- IONS 0.12
- Stochastic Oscillator
- VVV 50.98
- IONS 68.15
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.